DE68918761D1 - Therapeutische IgM-Konzentrate. - Google Patents

Therapeutische IgM-Konzentrate.

Info

Publication number
DE68918761D1
DE68918761D1 DE68918761T DE68918761T DE68918761D1 DE 68918761 D1 DE68918761 D1 DE 68918761D1 DE 68918761 T DE68918761 T DE 68918761T DE 68918761 T DE68918761 T DE 68918761T DE 68918761 D1 DE68918761 D1 DE 68918761D1
Authority
DE
Germany
Prior art keywords
compositions
prepared
weight
antibodies
igm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68918761T
Other languages
English (en)
Other versions
DE68918761T2 (de
Inventor
Michael S Collins
Hans Georg Opitz
John L Lundblad
Richard L Seng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of DE68918761D1 publication Critical patent/DE68918761D1/de
Publication of DE68918761T2 publication Critical patent/DE68918761T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE68918761T 1988-06-06 1989-05-24 Therapeutische IgM-Konzentrate. Expired - Fee Related DE68918761T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20337788A 1988-06-06 1988-06-06

Publications (2)

Publication Number Publication Date
DE68918761D1 true DE68918761D1 (de) 1994-11-17
DE68918761T2 DE68918761T2 (de) 1995-02-16

Family

ID=22753737

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68918761T Expired - Fee Related DE68918761T2 (de) 1988-06-06 1989-05-24 Therapeutische IgM-Konzentrate.

Country Status (8)

Country Link
EP (1) EP0345543B1 (de)
JP (1) JP2703341B2 (de)
AT (1) ATE112688T1 (de)
DE (1) DE68918761T2 (de)
DK (1) DK270389A (de)
ES (1) ES2060695T3 (de)
IE (1) IE64523B1 (de)
IL (1) IL90281A (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5029840A (en) * 1988-08-30 1991-07-09 Ricoh Company, Ltd. Automatic sheet feeder for an image recording apparatus
DK0764658T3 (da) * 1995-09-22 2002-04-22 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af immunoglobuliner ud fra fraktioner, som opstår ved fraktionering af blodplasma fra mennesker
JP4688457B2 (ja) * 2004-09-10 2011-05-25 四国乳業株式会社 免疫増強組成物
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US10570194B2 (en) 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
EP3275897A1 (de) 2016-07-27 2018-01-31 Biotest AG Verfahren zur herstellung von immunoglobulinzusammensetzungen
CN112409477B (zh) * 2019-08-21 2022-11-08 广东菲鹏生物有限公司 IgM纯化方法
KR20220166819A (ko) * 2020-04-10 2022-12-19 바누디스 게엠베하 예방 및 치료에서의 천연 항체
EP4178978A1 (de) * 2020-07-10 2023-05-17 Grifols Worldwide Operations Limited Verfahren zur herstellung einer zusammensetzung mit menschlichem, aus plasma stammendem immunglobulin m

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597409A (en) * 1970-05-25 1971-08-03 American Cyanamid Co Process for recoverring immunoglobulin a and immunoglobulin m
US3808189A (en) * 1973-03-15 1974-04-30 American Cyanamid Co Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol
US4604235A (en) * 1984-05-23 1986-08-05 J. T. Baker Chemical Company Purification of monoclonal antibodies

Also Published As

Publication number Publication date
JPH0267228A (ja) 1990-03-07
IL90281A (en) 1994-10-07
IE64523B1 (en) 1995-08-09
IL90281A0 (en) 1989-12-15
DE68918761T2 (de) 1995-02-16
EP0345543A3 (en) 1990-06-13
DK270389A (da) 1989-12-07
JP2703341B2 (ja) 1998-01-26
ES2060695T3 (es) 1994-12-01
ATE112688T1 (de) 1994-10-15
EP0345543B1 (de) 1994-10-12
IE891805L (en) 1989-12-06
EP0345543A2 (de) 1989-12-13
DK270389D0 (da) 1989-06-02

Similar Documents

Publication Publication Date Title
Lindahl et al. Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells.
Chaffee et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
EP0673255A4 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon.
Polhill Jr et al. Kinetic assessment of alternative complement pathway activity in a hemolytic system: II. Influence of antibody on alternative pathway activation
DE68918761D1 (de) Therapeutische IgM-Konzentrate.
ES2067600T3 (es) Procedimiento para la fabricacion de preparados de inmunoglobulina, que contienen igm y/o iga, no modificados de administracion intravenosa.
US4844895A (en) Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
Greisman et al. The nature of endotoxin tolerance.
US5510465A (en) Heat-treated IgM antibody preparations
KR900701320A (ko) 호산구증다증을 억제시키거나 경감시키는 방법
Lindahl et al. Enhanced expression of histocompatibility antigens of lymphoid cells in mice treated with interferon
Harvath et al. Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia
FI924215A (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen
Prokopenko et al. Effect of the polyvalent proteinase inhibitor trasylol on antibody formation under normal conditions and in experimental atherosclerosis
SE9300139L (sv) Framställning av ett nytt läkemedel
Pitts et al. The antibody responses to myelin basic protein (BP) in Lewis rats: the effects of Bordetella pertussis
ATE175357T1 (de) Empfängnisverhütender impfstoff
Bhoopalam et al. Effect of dextran-S (alpha, 1-3 dextran) on the growth of plasmacytomas MOPC-104E and J558.
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
Toyama et al. Inhibition of Sendai virus-induced hemolysis by concanavalin A
Mazumder et al. 1006 IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES BY INTERLEUKIN-2 (IL-2)
Moen et al. 1008 THEORETICAL AND BIOLOGICAL CONSIDERATIONS IN SUCCESSFUL MISMATCHED BONE MARROW TRANSPLANTATION
Mann et al. 1005 IN VITRO EFFECTS OF COMMERCIAL FACTOR VIII CONCENTRATES (FC) ON THE FUNCTION OF NORMAL LYMPHOCYTES
McClead et al. 1007 ORAL ANTI-PSEUUOMONAS (Ps) IgG PROVIDE SPECIFIC IMMUNE PROTECTION AGAINST PS SEPSIS DURING CYCLOPHOSPHAMIDE-INDUCED LEUKOPENIA

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee